Sonnet Biotherapeutics Holdings IncNASDAQ:SONN
- LAST PRICE2.8900
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.8900/ 1
- Ask / Lots3.0000/ 3
- Open / Previous Close--- / 2.8900
- Day Range---
- 52 Week Range
- Volume22
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SONN |
|---|---|---|
| 09:32 ET | 841 | 2.88 |
| 09:37 ET | 240 | 2.9593 |
| 09:42 ET | 250 | 2.897 |
| 09:46 ET | 10050 | 2.9 |
| 10:15 ET | 1394 | 2.91 |
| 10:38 ET | 260 | 2.9783 |
| 10:56 ET | 2000 | 2.94 |
| 11:00 ET | 2040 | 2.94 |
| 11:05 ET | 1685 | 3 |
| 11:07 ET | 200 | 3 |
| 11:09 ET | 3088 | 3.07 |
| 11:12 ET | 9794 | 2.96 |
| 11:14 ET | 100 | 2.96 |
| 11:16 ET | 700 | 3.01 |
| 11:21 ET | 138 | 3.01 |
| 11:45 ET | 200 | 3 |
| 12:26 ET | 696 | 3 |
| 12:32 ET | 1700 | 3.01 |
| 12:37 ET | 800 | 3 |
| 12:39 ET | 3000 | 2.9745 |
| 12:42 ET | 500 | 2.964038 |
| 12:50 ET | 1098 | 2.96 |
| 01:04 ET | 1500 | 2.96 |
| 01:26 ET | 496 | 2.96 |
| 01:29 ET | 100 | 2.947 |
| 01:31 ET | 700 | 3.01 |
| 01:33 ET | 100 | 3.01 |
| 01:38 ET | 270 | 2.99 |
| 01:45 ET | 200 | 3.01 |
| 01:47 ET | 4983 | 2.95 |
| 02:05 ET | 122 | 2.94 |
| 02:34 ET | 1180 | 2.94 |
| 02:39 ET | 100 | 2.94 |
| 03:14 ET | 200 | 2.94 |
| 03:15 ET | 679 | 2.91 |
| 03:28 ET | 100 | 2.91 |
| 03:32 ET | 760 | 2.9 |
| 03:48 ET | 949 | 2.91 |
| 03:53 ET | 346 | 2.9 |
| 04:00 ET | 2072 | 2.89 |
Nov 12, 2024
Sonnet BioTherapeutics Releases Virtual Investor '"What this Means" Segment, from 9:15AM ET on Tuesday Nov 12, 2024 by Dow Jones
9:15AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 6, 2024
Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules, from 1:20PM ET on Wednesday Nov 06, 2024 by Dow Jones
1:20PM ET on Wednesday Nov 06, 2024 by Dow JonesSonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates, from 8:30AM ET on Wednesday Nov 06, 2024 by Dow Jones
8:30AM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sonnet Biotherapeutics Holdings Inc | 2.4M | -0.1x | --- |
Halberd Corp | 2.4M | 1.6x | --- |
Aclarion Inc | 1.9M | 0.0x | --- |
Qrons Inc | 2.3M | -5.6x | --- |
Scinai Immunotherapeutics Ltd | 2.6M | -0.3x | --- |
Phio Pharmaceuticals Corp | 2.7M | -0.2x | --- |
Company Information
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. Its technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. It designed the FHAB construct to improve drug accumulation in tumors, and to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12, covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical stage asset, SON-080, is the native human version of IL-6 that is manufactured in Chinese Hamster Ovary cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy and Diabetic Peripheral Neuropathy. Its pipeline also includes SON-1210, SON-1410 and SON-3015.
Contact Information
- Headquarters
- 100 Overlook Center, Suite 102PRINCETON, NJ, United States 08540
- Phone
- 609-375-2227
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer
- Pankaj Mohan
- Chief Financial Officer
- John Cross
- Chief Technical Officer
- Susan Dexter
- Chief Scientific Officer
- John Cini
- Chief Medical Officer
- Richard Kenney
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.4M |
|---|---|
Revenue (TTM) | $55.9K |
Shares Outstanding | 837.7K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.48 |
EPS | $-24.17 |
Book Value | $-1.03 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 43.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -14,271.32% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
